CLDN18 and gastroesophageal junction adenocarcinoma: It was granted a priority review by the Food and Drug Administration (FDA) in 2023 for patients with locally advanced, inoperable or metastatic GC/GEJ with moderate to strong expression of CLDN18.2, HER2 negative GC or GEJ adenocarcinoma [42, 43].